JUL 19, 2017
EvokeDx, a device capable of objectively assessing central vision function and diagnosing glaucoma, has received the CE mark, according to a press release from manufacturer Konan Medical.
Approved in the United States since late 2014, the device is designed to assess both visual function as well as retina-specific dysfunction. Visual function is assessed using measurements of visual evoked potentials (VEP). Measurements of retina-specific dysfunction are assessed using electroretinograms (ERG).
EvokeDx features a patented isolated check VEP (icVEP), a low-contrast, high temporal frequency stimulus which was validated in a multicenter clinical trial for rapid and objective assessment of glaucomatous damage.
“In the NIH-sponsored trials, our icVEP strategy had a classification accuracy of 89% to 94% for glaucoma,” said Vance Zemon, PhD, professor at Yeshiva University, Albert Einstein College of Medicine Campus, and co-inventor of EvokeDx.
The platform consists of several components, including an intuitive touch-screen user interface, LED stimulus display and infrared gaze and attention monitoring.
EvokeDx will be featured at the European Ophthalmology meeting (ESCRS) in Lisbon in October 2017.